Lutetium Lu-177 dotatate · Nutrient Desk

What is Lutetium Lu-177 dotatate?

Lutetium-177 DOTATATE is a targeted radiopharmaceutical used to treat selected somatostatin-receptor-positive neuroendocrine tumours. It combines a receptor-binding peptide with a radioactive therapeutic payload. 1 2

How it works

DOTATATE binds somatostatin receptors, carrying lutetium-177 towards receptor-bearing tissue. The emitted radiation damages cells; the same targeting principle can be used separately for diagnostic imaging. 2

Effects studied

Neuroendocrine tumour progression

NETTER-1 assessed progression-free survival in a defined neuroendocrine tumour population. The result supports a specific treatment setting rather than a claim of cure.

Evidence: Randomised clinical trial. 1

What does the evidence show?

The retained NETTER-1 paper addresses a defined neuroendocrine-tumour population. It supports a specific clinical question rather than a general claim about treating all cancers.

The targeting idea

DOTATATE binds to somatostatin receptors. When paired with lutetium-177, that targeting can bring radiation to receptor-bearing tissue. This is peptide receptor radionuclide therapy: the peptide helps with delivery, while the radionuclide supplies the therapeutic radiation. It is not an ordinary peptide injection.

What needs to match before treatment

Tumour type, receptor expression, disease behaviour and organ function all matter. A positive receptor-imaging scan is one piece of that assessment, not an automatic instruction to treat. Gallium-68 DOTATATE is a related imaging tracer, but its purpose and radioactive component are different.

How the trial result should be read

NETTER-1 evaluated outcomes including progression-free survival in a particular group of patients. This measures the time before defined disease progression or death. It does not guarantee a cure, and applying the result to other tumours would require further evidence. 1

Why specialist follow-up is essential

Treatment requires monitoring for effects on bone marrow, kidneys and liver. Protective amino-acid infusions and radiation precautions are required parts of care. Longer-term concerns include secondary marrow disorders and fertility effects. The clinical team weighs these risks against the benefit using the current product information. 2

Safety & status

Treatment requires specialist radiation precautions and monitoring of blood counts, kidney and liver function. Kidney-protective amino-acid infusions form part of clinical administration; longer-term marrow and reproductive risks also matter. 2

Country and product status

This introduction describes the molecule and its research context. Product availability, approved indications and eligibility in Germany and Switzerland require a current local product check; they are not established by an overseas study or an online listing.

Frequently asked questions

Is this the same as a gallium-68 DOTATATE scan?

No. Both use receptor targeting, but gallium-68 provides a diagnostic signal while lutetium-177 provides therapeutic radiation.

Why does receptor status matter?

The treatment relies on somatostatin-receptor binding. A neuroendocrine tumour diagnosis alone does not establish suitability. 2

Sources

This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.

Lutetium Lu-177 dotatate: paper 10.1056/NEJMoa1607427 Research reference · Retained archive reference; not independently checked for this draft.
Lutetium Lu-177 dotatate: www.novartis.com reference Reference or product information · Retained archive reference; not independently checked for this draft.

Research provenance

This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.